The 500 basis point gross margin expansion over the past two years suggests that Lilly's portfolio is increasingly weighted toward high-value biologics with limited price competition. Operating margin, however, dipped to 39.1% in 2026Q2 from 45.8% a year earlier, which may reflect temporary cost pressures from manufacturing scale-up and launch-related SG&A. Net margin volatility, swinging from 8.5% in 2024Q3 to 37.4% in 2026Q1, warrants monitoring for one-time tax items or non-operating gains that could distort underlying earning power.

The dramatic rise in ROE from 18.9% in 2024Q1 to over 100% in 2026Q2 is driven by both expanding net margins and a shrinking equity base due to aggressive buybacks and debt-funded expansion. ROIC, however, has remained relatively stable in the 8-11% range over the same period, indicating that the incremental capital invested in manufacturing and acquisitions is generating returns that are not yet fully reflected in the metric. This divergence suggests that while equity holders are benefiting from financial leverage, the underlying operational returns on invested capital are still maturing.

The 125-day deterioration in CCC is primarily attributable to DIO rising from 264 to 436 days, reflecting the massive build-up of inventory to support GLP-1 manufacturing scale-up and anticipated demand. DSO has improved modestly from 111 to 88 days, suggesting better receivables collection, while DPO has increased from 113 to 155 days, indicating extended supplier payment terms. The persistent negative working capital changes, as noted in cash flow analysis, underscore that inventory build is absorbing cash, which may pressure near-term free cash flow despite strong operating income.

Despite the increase in absolute debt, interest coverage remains comfortable at 26.8x in 2026Q2, up from 15.1x in 2024Q1, indicating that operating income is more than sufficient to service debt. However, the D/EBITDA ratio has deteriorated from 8.36 in 2024Q1 to 5.94 in 2026Q2, suggesting that EBITDA growth is outpacing debt accumulation, which is a positive sign. The leverage increase is largely funding capacity expansion and acquisitions, which could enhance returns if the GLP-1 market continues to grow, but it also amplifies downside risk if demand disappoints.

The quick ratio of 1.00 in 2026Q2 indicates that liquid assets barely cover current liabilities, but the high inventory levels (DIO of 436 days) suggest that a portion of current assets is tied up in slow-moving stock. Under a severe demand shock, the inventory could become a liquidity drag, though the strong operating cash flow generation (FCF margin of 33.8% in 2026Q2) provides a more reliable buffer. The company's access to debt markets, evidenced by recent bond issuances, further supports liquidity, but investors should monitor the refinancing risk given the rising debt load.